Investor News
-
U.S. FDA accepts Bayer’s supplemental New Drug Application for finerenone in chronic kidney disease without diabetes
Not intended for U.S. and UK Media
The supplemental New Drug Application (sNDA) was based on the positive Phase III FIND-CKD study results, which demonstrated that finerenone significantly delayed kidney disease progression and reduced cardiovascular-kidney events in addition to …
Company plans to build state-of-the-art site in New Albany, Ohio, U.S., to serve patients in the U.S. as well as globally / Bayer expects to create around 600 new high-value jobs in the area / Multi-year investment reinforces U.S. business …
Bayer places 2 billion euro hybrid bonds
NOT FOR DISTRIBUTION IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, SOUTH AFRICA OR JAPAN
Dual tranche with non-call periods of six and nine years
U.S. FDA approves finerenone for new indication in patients with chronic kidney disease associated with type 1 diabetes
Not intended for U.S. and UK Media
Kerendia™ is the first FDA-approved treatment option in more than 30 years for adults with chronic kidney disease (CKD) associated with type 1 diabetes (T1D) / Approval addresses an important unmet need for a population at increased risk of …
U.S. FDA grants accelerated approval to Bayer’s targeted therapy sevabertinib as a first-line treatment option for adults with HER2-mutant non-small cell lung cancer
Not intended for U.S. and UK Media
Accelerated approval of sevabertinib for patients with advanced HER2-mutant non-small cell lung cancer (NSCLC) follows FDA Priority Review and Breakthrough Therapy Designations, and reflects the potential for sevabertinib to provide substantial …
Commitment aims to support the growth of winter canola in the Southern Great Plains of the U.S., as a feedstock for renewable diesel and sustainable aviation fuel
Commercialization of two blockbusters already started, with additional launches expected over the next years / Bayer announces genome-edited standable soy and development of herbicide tolerant trait to correspond with Icafolin, a unique crop …
Bayer’s sevabertinib approved in Japan for patients with HER2-mutant non-small cell lung cancer
Not intended for U.S. and UK Media
First targeted therapy approved in Japan for this indication, with use across all lines of therapy, including first-line treatment / Approval is based on results from the ongoing Phase I/II SOHO-01 trial evaluating the efficacy and safety of …
Bayer operationally on track, decisive progress on strategic priorities
Second quarter of 2026:
Group sales increase 2.2 percent (Fx & portfolio adj.) to 10.872 billion euros / EBITDA before special items rises 1.9 percent to 2.144 billion euros / Crop Science posts higher sales and substantial earnings growth / Pharmaceuticals sales at …
Bayer submits application for next indication of Kerendia in China
Not intended for U.S. and UK Media
Regulatory submission of new indication for patients with non-diabetic chronic kidney disease is based on positive data from the Phase III FIND-CKD study, presented at the 63rd European Renal Association (ERA) Congress 2026 and simultaneously …
Bayer successfully places new U.S. dollar bonds with a volume of 5 billion
NOT FOR DISTRIBUTION IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, SOUTH AFRICA OR JAPAN
Leverkusen, July 15, 2026 – The Bayer Group successfully placed bonds with a volume of 5 billion U.S. dollars on Wednesday, which will be issued by its subsidiary Bayer US Finance LLC, St. Louis, United States, and guaranteed by Bayer AG. …